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Abstract: In this article we will review the role of long acting 2-adrenoreceptor agonists and long-acting muscarinic 
agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once 
daily inhaled 2-adrenoreceptor agonists. Pharmacologically this drug is a nearly full 2-agonist without loss of efficacy 
after prolonged administration. We will also discuss its dosing, safety and tolerability. 
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ROLE OF LONG ACTING 2-ADRENORECEPTOR 
AGONISTS AND LONG-ACTING MUSCARINIC 
AGENTS IN THE MANAGEMENT OF AIRFLOW 
OBSTRUCTION 
  International guidelines on chronic obstructive pulmo-
nary disease (COPD) and bronchial asthma [1, 2] underline 
the clinical benefit derived from including long acting bron-
chodilators in their therapeutic approach. The current gold 
standard therapy for treating patients with moderate-to-
severe persistent asthma is the combination of a long acting 
2-adrenoreceptor agonist (LABA) with an inhaled corticos-
teroid. Long acting 2-adrenoreceptor agonists (LABAs) 
have also a well established role in the treatment of stable 
COPD. It is well known that a simplified dosing regimen 
will improve patients’ compliance [3], a key point in multi-
step therapeutic regimens such as those that are often pre-
scribed to individuals with COPD or asthma. That is why 
long acting agents, particularly once-daily inhalers, will offer 
a better adherence than other drugs that require a more com-
plicated dosing schedule. 
  LABAs are highly lipophilic compounds. This character-
istic helps to prolong their duration of action since they dis-
sociate more slowly than short-acting 2-agonists from lung 
fat-soluble tissues. Formoterol and salmeterol have been the 
LABAs usually prescribed by most clinicians during the last 
decades [4]. However, a few drugs have been developed for 
the last years to attempt to improve the therapeutic profile of 
these classical LABA. Ultra-LABA is the term used to de-
scribe a variety of new 2-adrenoreceptor agonists that have 
focused their action in a more prolonged half life with the 
aim of making feasible a one-day dose administration. In-
dacaterol (QAB-149), carmoterol (CHF-4226, TA-2005), 
GSK-159797, and GSK-642444 are some of these new   
ultra-LABAs that are still in different phases of clinical de-
velopment [5, 6]. 
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  Parallel to what happens with 2-adrenoreceptor agonists 
new long acting antimuscarinic agents (LAMAs) are also 
under preclinical development in an attempt to improve 
some aspects of the excellent therapeutic profile that tiotro-
pium has shown since this drug has become commercially 
available [7]. Aclidinium, NVA237, OrM3, and CHF 5407 
are some of these new LAMAs which are also in different 
phases of preclinical development. The combination of a 
long acting 2-adrenoreceptor agonist (LABA) and a long-
acting muscarinic agent (LAMA) is an innovative approach 
that will most likely be a significant therapeutic progress in a 
selected population of patients with airflow obstruction. 
However, further studies are clearly warranted before we can 
define which population of patients will really benefit from 
these future therapeutic combined agents. 
  This review focuses on indacaterol (QAB 149; Novartis, 
Basel, Switzerland) [8, 9], one of the new once daily inhaled 
2-adrenoreceptor agonists that has completed phase II and 
phase III clinical trials for the treatment of asthma and 
COPD. 
INDACATEROL: ACTIVITY PROFILE 
  Pharmacologically, indacaterol is a nearly full 2-agonist 
[10]. Tissue and experimental studies show longer durations 
of action for indacaterol when compared to salmeterol or 
formoterol, demonstrating sustained bronchodilator efficacy 
throughout the full 24-hour period [11, 12]. In a human lung 
slice model Sturton et al. [13] have demonstrated that in-
dacaterol has a superior activity than salmeterol and a similar 
intrinsic efficacy to formoterol. Onset of action, with a fast 
acting action, is very similar for indacaterol and formoterol 
and slower for salmeterol. This experimental finding corre-
lates well with what has been observed in initial clinical 
studies, since a statistically significant beneficial effect is 
demonstrated in those patients receiving indacaterol within 
the first 5 minutes after inhalation. A rapid onset of effect 
may increase patients’ confidence in treatment and subse-
quently improve therapy compliance. Opposite to this rapid 
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improvement in FEV1 occurs within 15 minutes after inhala-
tion. Functional data show highest, about twofold, intrinsic 
activity for formoterol and indacaterol than for salbutamol or 
salmeterol [8]. 
INDACATEROL: DOSING 
 Rennard  et al. [14] conducted a dose-ranging study, with 
a tiotropium comparison, to elucidate which dose of in-
dacaterol shows 24-hour effectiveness in patients with mod-
erate-to-severe COPD. Functional inclusion criteria were 
prebronchodilator FEV1  40% of predicted, FEV1  1.0 L, 
and FEV1/FVC < 70%. Six hundred thirty five patients were 
eventually randomized to receive 50, 100, 200 or 400 g or 
placebo once daily for 7 days. All indacaterol doses signifi-
cantly increased FEV1 from 5 minutes to 24 hours post-dose 
but 400 and 200 g were the dose most effective. A subset of 
subjects from each treatment group entered an open label 
extension and received tiotropium 18 g once daily for 8 
days. Indacaterol through FEV1 levels compared favorably 
with the improvement observed by day 8 in patients that 
received tiotropium in this subgroup of patients taking part 
in the open-label extension. Overall, a 400 g dose was the 
most effective in this study. 
 Single  200  g and 400 g doses provide effective and 
sustained 24-hour bronchodilator control and a rapid onset of 
action (< 5 minutes) in asthmatic patients. A 200 g dose 
seems to be the optimum dose regarding efficacy and safety 
balance. On another dose-ranging study designed to establish 
the optimal dose for indacaterol inhaled treatment in patients 
with persistent asthma, LaForce et al. [15] also reported that 
a 200 g dose seems to offer the best efficacy/safety balance 
in most subjects. 
INDACATEROL: TACHYPHYLAXIS 
  It has been stated that 2 adrenoreceptor downregulation 
may follow chronic administration of LABAs in asthma. The 
consequence would be a subsequent reduced sensitivity, 
known as tachyphylaxis, of airway smooth muscle and in-
flammatory cells response. It must be emphasized that 
tachyphylaxis has not been observed with long-term in-
dacaterol administration. Many studies have shown that there 
is no loss of efficacy with prolonged administration of in-
dacaterol since sustained improvements on FEV1 are consis-
tently observed in those clinical trials that have addressed 
this issue. A low need of rescue medication in the in-
dacaterol arm has also been occasionally highlighted in some 
comparative clinical trials of indacaterol and other LABAs. 
INDACATEROL: INTERACTION WITH SHORT 
ACTING BETA2-ADRENERGIC AGENTS (SABAs) 
  The interaction of indacaterol, formoterol and salmeterol 
with the short acting adrenergic agent isoprenaline was 
evaluated by Naline et al. [16] on a nice study with isolated 
human bronchi. These authors show that indacaterol and 
formoterol behave as full agonists and do not antagonize the 
isoprenaline-induced bronchi relaxation response in an iso-
lated human bronchi model using preparations pre-
contracted with carbachol. The lack of antagonism with 
short-acting agonists may have potential clinical connota-
tions regarding the use of SABA as rescue therapy in com-
mon clinical practice. Other findings from the study reported 
by Naline et al. [17] were that indacaterol showed an onset 
of action similar to that of salbutamol and duration of action 
> 12 hours. 
INDACATEROL 
  Previous studies in patients and healthy volunteers have 
shown that LABAs may be associated with 2 mediated 
systemic adverse effects such as skeletal muscle tremor, 
headache, nervousness, palpitations with changes in heart 
rate, prolongation of the QTc interval, and increased glucose 
and potassium blood levels [18-25]. On the basis of these 
data, safety and tolerability studies have been conducted to 
evaluate indacaterol effect on these parameters. An optimal 
safety profile is mandatory for a drug, such as indacaterol, 
characterized by a 24-hour bronchodilator efficacy at once-
daily dosing. 
  In asthma patients’ indacaterol offers an excellent overall 
safety profile since even a high dose of 1000 g has not been 
found to be associated with any sustained systemic adverse 
effect [26-28]. It is worthwhile pointing out that a dose of 
1000  g is obviously a clearly supratherapeutic dosing, 
which is five-fold the standard dose in asthma; this feature 
deserves to be emphasized since in clinical practice some 
patients may self-administer additional doses of the drug as 
rescue medication or accidentally. 
  In the COPD setting, once-daily indacaterol at doses up 
to 800 g has been well tolerated. A prospective randomized 
comparative study on 163 patients with COPD receiving 
placebo or 400 g or 800 g of indacaterol did not show any 
statistically significant difference at any dose on mean pulse 
rate and QTc interval [29]. As it has been observed in safety 
studies in asthma population [30], small differences, consid-
ered to be without any clinical relevance, were found on 
serum potassium levels, mean blood glucose levels and mean 
blood pressure. 
  Although no serious adverse effects are found in safety 
studies on indacaterol, mild cough is a relatively common 
adverse effect [31]. A short duration, less than 2 minutes 
post-dose, and the lack of bronchospasm of any degree are 
distinctive features of this indacaterol-induced cough. It has 
been reported in up to 14.7% of patients receiving this in-
haled drug at a dose of 400 g daily and in up to 28.4% in 
those receiving an 800 g daily dose. It is worthwhile re-
membering that an 800 g dose represents at least 2 times 
the usual therapeutic dose suggested by initial studies. In a 
different series of COPD patients treated with more standard 
doses of indacaterol mild and short-lived cough occurred in a 
dose-related form, with an incidence that ranged from 2.9% 
with a 50 g dose to 12.4% with a 400 g dose. This cough 
is almost always of mild intensity; it usually appears with 
initial administration of the drug and declines progressively 
after a few days of treatment. In the study published by Ren-
nard et al. [14] the incidence of cough by day 7 was similar 
to that observed with placebo. More interestingly, by the first 
month of treatment no patients receiving indacaterol com-
plain about cough. 
  Researchers have realized that a very low drop-out rate 
has been consistently observed in the indacaterol arm of 
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good safety and tolerability profile of this inhaled ultra-
LABA. However, a word of caution is still warranted since a 
common pitfall of most new LABAs trials, including those 
that focus on indacaterol, is that the duration of the studies is 
in general relatively short. Consequently, more long-term 
studies are warranted to definitely confirm its impressive 
bronchodilator efficacy and continued safety over time. 
PRESSURIZED METERED-DOSE INHALER (MDI) 
VERSUS SINGLE-DOSE DRY POWER INHALER 
(SDDPI) 
  Indacaterol has proven to be equally effective given ei-
ther by hydrofluoroalkane (HFA) pressurized metered-dose 
inhaler or single-dose dry power inhaler. A recent study on 
patients with COPD has established the SDDPI as the pre-
ferred system to inhale the drug and this device will be the 
usual way of administering indacaterol when the drug be-
comes commercially available [32]. Moreover, dosages used 
in this last study (150 g, 300 g and 600 g) will also most 
likely be the recommended doses when the drug eventually 
comes out. 
COMBINATION THERAPY WITH INDACATEROL 
AND NVA237 (GLYCOPYRROLATE) 
  As stated before, preliminary reports suggest that the 
combination of a LABA and a LAMA may provide a thera-
peutic benefit in some patients with chronic airflow obstruc-
tions although this potential benefit has not been consistently 
identified in all published studies that have addressed this 
issue. It well could be that the choice of both a determined 
long acting 2-adrenoreceptor agonist and a long-acting 
muscarinic agent is one of the potentially crucial variables to 
explain some of the discrepancies found among different 
studies. A fixed dose combination of indacaterol and 
NVA237 for once-daily treatment of COPD is also under 
development. Ongoing clinical trials using this combination 
will certainly help to clarify this subject in the future. 
  There is some evidence suggesting an optimal safety 
profile for NVA237: a low systemic absorption is one of the 
pharmacokinetic characteristics of inhaled NVA237 and it is 
associated with a low effect of this drug on cardiovascular 
parameters when compared to tiotropium [33]. Although this 
finding supports a more favorable safety profile for NVA237 
it still remains unclear if this difference really may imply any 
clinically significant impact on common clinical practice. 
Improvements in lung function with NVA237 seem to be 
comparable to those observed with tiotropium
 [34] but in-
haled NVA237 does not produce the dry mouth side effect 
that is often reported with other antimuscarinic drugs. Phase 
III studies have shown a rapid onset, about 5 minutes post-
dose, of bronchodilator effect. A sustained improvement if 
FEV1 has been observed when a dose  120 g of NVA237 
has been administered in these studies. 
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